Genentech/Novartis Xolair
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amendment to Genentech/Novartis' Xolair (omalizumab) BLA will be submitted by year-end, with an expected six-month review from FDA, Genentech tells analysts. The amendment will include data from the firms' 1,900-patient safety study, ALTO, bringing the total safety database to over 4,000 patients. FDA had deemed the size of the Xolair safety database inadequate and requested platelet monitoring safety data from ALTO, as well as data on subgroups and pharmacokinetics. The BLA, submitted in June 2000 for moderate to severe allergic asthma in adults and adolescents, received a "complete response" letter in July 200
You may also be interested in...
PDL/Roche Targeting Broad Zenapax Asthma Label Under Development Deal
Roche/Protein Design Labs will pursue a broad moderate to severe asthma indication for Zenapax (daclizumab) in an attempt to gain an advantage over Xolair, under a co-development agreement announced Sept. 16.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.